Trials / Terminated
TerminatedNCT02231580
Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients
A Dose Escalation, Proof of Concept, Phase IIa Study to Investigate the Safety and Tolerability, the Pharmacokinetic and the Pharmacodynamic of BN82451B, Administered Twice Daily Over 4 Weeks, in Male Patients With Huntington's Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- Male
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BN82451B versus placebo after oral administration twice daily (bid) for 28 days in patients with Huntington's Disease (HD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BN82451B | BN82451B capsule |
| DRUG | Placebo | Placebo capsule |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2016-03-31
- Completion
- 2016-03-31
- First posted
- 2014-09-04
- Last updated
- 2019-01-15
- Results posted
- 2018-01-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02231580. Inclusion in this directory is not an endorsement.